Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11775)
All Articles published online
|
Publishing Process of This Article
|
Nov 7, 2020 (publication date) through Jul 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Damiris K, Tafesh ZH, Pyrsopoulos N. Efficacy and safety of anti-hepatic fibrosis drugs. World J Gastroenterol 2020; 26(41): 6304-6321 [PMID: 33244194 DOI: 10.3748/wjg.v26.i41.6304] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i41/6304.htm |
| Number | Citing Articles |
| 1 |
Siyu Yu, Guang Ji, Li Zhang. The role of p53 in liver fibrosis. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.1057829
|
| 2 |
Pengying Liao, Huayu Liu, Xueqin Sun, Xinrui Zhang, Miao Zhang, Xianyou Wang, Jun Chen. A novel ACE inhibitory peptide from Pelodiscus sinensis Wiegmann meat water-soluble protein hydrolysate. Amino Acids 2024; 56(1) doi: 10.1007/s00726-024-03399-1
|
| 3 |
Mingfa Chen, Zhiguo Wu, Zhan Du, Shuilin Sun, Jun Wu, Jie Luo. Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting liver fibrosis in patients with chronic hepatitis B: A meta-analysis. Gastroenterología y Hepatología 2022; 45(5): 361 doi: 10.1016/j.gastrohep.2021.10.001
|
| 4 |
Paula Sánchez Sánchez, María del Mar Rigual, Nabil Djouder. Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development. Cancers 2021; 13(20): 5045 doi: 10.3390/cancers13205045
|
| 5 |
Xia Niu, Xiaomei Wang, Bingyu Niu, Yanan Meng, Hongwei He, Yucheng Wang, Guiling Li. Costunolide Loaded in pH-Responsive Mesoporous Silica Nanoparticles for Increased Stability and an Enhanced Anti-Fibrotic Effect. Pharmaceuticals 2021; 14(10): 951 doi: 10.3390/ph14100951
|
| 6 |
Nan Chen, Yu Sun, Pengyu Luo, Yuna Tang, Yuchen Fan, Liyan Han, Kai Wang. Association of CXCR4 gene expression and promoter methylation with chronic hepatitis B-related fibrosis/cirrhosis. International Immunopharmacology 2024; 139: 112686 doi: 10.1016/j.intimp.2024.112686
|
| 7 |
Sina Ghandian, Rahul Thapa, Anurag Garikipati, Gina Barnes, Abigail Green‐Saxena, Jacob Calvert, Qingqing Mao, Ritankar Das. Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis. JGH Open 2022; 6(3): 196 doi: 10.1002/jgh3.12716
|
| 8 |
Arshi Khanam, Paul G. Saleeb, Shyam Kottilil. Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?. Cells 2021; 10(5): 1097 doi: 10.3390/cells10051097
|
| 9 |
Wei-yi Cheng, Xi-xi Zeng, Ping Cheng, Jin-xiang Zhang. Loureirin B ameliorates cholestatic liver fibrosis via AKT/mTOR/ATG7-mediated autophagy of hepatic stellate cells. European Journal of Pharmacology 2024; 971: 176552 doi: 10.1016/j.ejphar.2024.176552
|
| 10 |
Guoqing Li, Juanni Lu, Chuanhao Wang, Xuliang Chang, Zhuo Qu, Wannian Zhang, Chunlin Zhuang, Zhenyuan Miao, Weiheng Xu. Discovery of Sophoridine α-Aryl Propionamide Derivative ZM600 as a Novel Antihepatic Fibrosis Agent. Journal of Medicinal Chemistry 2024; 67(13): 11389 doi: 10.1021/acs.jmedchem.4c01010
|
| 11 |
Minghui Zheng, Jing Li, Weizhen Fang, Ling Luo, Rui Ding, Hua Zeng, Hong Luo, Xianghua Lin, Chaohui Duan. The TNF-α rs361525 and IFN-γ rs2430561 polymorphisms are associated with liver cirrhosis risk: a comprehensive meta-analysis. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1129767
|
| 12 |
Xia Niu, Xiaomei Wang, Bingyu Niu, Guoqing Li, Xinyi Yang, Yucheng Wang, Guiling Li. Novel IMB16-4 Compound Loaded into Silica Nanoparticles Exhibits Enhanced Oral Bioavailability and Increased Anti-Liver Fibrosis In Vitro. Molecules 2021; 26(6): 1545 doi: 10.3390/molecules26061545
|
| 13 |
Xueliang Yi, Xuemei Tang, Tianlong Li, Lin Chen, Hongli He, Xiaoxiao Wu, Chunlin Xiang, Min Cao, Zixiang Wang, Yi Wang, Yiping Wang, Xiaobo Huang. Therapeutic potential of the sphingosine kinase 1 inhibitor, PF-543. Biomedicine & Pharmacotherapy 2023; 163: 114401 doi: 10.1016/j.biopha.2023.114401
|
| 14 |
Yaxin Wang, Canyan Wu, Jiahui Zhou, Haiming Fang, Jiajia Wang. Overexpression of estrogen receptor β inhibits cellular functions of human hepatic stellate cells and promotes the anti-fibrosis effect of calycosin via inhibiting STAT3 phosphorylation. BMC Pharmacology and Toxicology 2022; 23(1) doi: 10.1186/s40360-022-00617-y
|
| 15 |
Mustafa Ghanim, Johnny Amer, Ahmad Salhab, Nidal Jaradat. Ecballium elaterium improved stimulatory effects of tissue-resident NK cells and ameliorated liver fibrosis in a thioacetamide mice model. Biomedicine & Pharmacotherapy 2022; 150: 112942 doi: 10.1016/j.biopha.2022.112942
|
| 16 |
Xia Niu, Yanan Meng, Yucheng Wang, Guiling Li. Established new compound IMB16-4 self-emulsifying drug delivery systems for increasing oral bioavailability and enhancing anti-hepatic fibrosis effect. Biomedicine & Pharmacotherapy 2022; 154: 113657 doi: 10.1016/j.biopha.2022.113657
|
| 17 |
Asma Ahrari, Hossein Najafzadehvarzi, Ali Taravati, Fatemeh Tohidi. The inhibitory effect of PLGA-encapsulated berberine on hepatotoxicity and α-smooth muscle actin (α-SMA) gene expression. Life Sciences 2021; 284: 119884 doi: 10.1016/j.lfs.2021.119884
|
| 18 |
Hong-Jie Chen, Jin-Yuan Huang, Chih-Yuan Ko, Pier P. Sainaghi. Peach Kernel Extracts Inhibit Lipopolysaccharide-Induced Activation of HSC-T6 Hepatic Stellate Cells. International Journal of Clinical Practice 2022; 2022: 1 doi: 10.1155/2022/4869973
|
| 19 |
Shihao Zheng, Chengyuan Xue, Size Li, Xiaobin Zao, Xiaoke Li, Qiyao Liu, Xu Cao, Wei Wang, Wenying Qi, Hongbo Du, Peng Zhang, Yongan Ye. Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1381476
|
| 20 |
Yan Xue, Meng Zhang, Tao Li, Feng Liu, Li-Xin Zhang, Xiao-Ping Fan, Bao-Hua Yang, Lei Wang. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World Journal of Gastroenterology 2021; 27(14): 1497-1506 doi: 10.3748/wjg.v27.i14.1497
|
| 21 |
Mingfa Chen, Zhiguo Wu, Zhan Du, Shuilin Sun, Jun Wu, Jie Luo. Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting liver fibrosis in patients with chronic hepatitis B: A meta-analysis. Gastroenterología y Hepatología (English Edition) 2022; 45(5): 361 doi: 10.1016/j.gastre.2021.10.003
|
| 22 |
Tzu-Yu Pu, Kai-Cheng Chuang, Min-Che Tung, Chih-Ching Yen, Yu-Hsuan Chen, Abdulkadir Cidem, Chu-Hsun Ko, Wei Chen, Chuan-Mu Chen. Lactoferrin as a therapeutic agent for attenuating hepatic stellate cell activation in thioacetamide-induced liver fibrosis. Biomedicine & Pharmacotherapy 2024; 174: 116490 doi: 10.1016/j.biopha.2024.116490
|
| 23 |
Shaofang Chen, Danping Zhuang, Qingyun Jia, Bing Guo, Genwen Hu. Advances in Noninvasive Molecular Imaging Probes for Liver Fibrosis Diagnosis. Biomaterials Research 2024; 28 doi: 10.34133/bmr.0042
|
| 24 |
Kehuan Yin, Xuedong Li, Xiaomin Luo, Yuru Sha, Puyang Gong, Jian Gu, Rui Tan, Rômulo Dias Novaes. Hepatoprotective Effect and Potential Mechanism of Aqueous Extract from Phyllanthus emblica on Carbon-Tetrachloride-Induced Liver Fibrosis in Rats. Evidence-Based Complementary and Alternative Medicine 2021; 2021: 1 doi: 10.1155/2021/5345821
|
| 25 |
Nabila Zein, Fathy Yassin, Shaza Makled, Saqer S. Alotaibi, Sarah M. Albogami, Gomaa Mostafa-Hedeab, Gaber El-Saber Batiha, Yaser Hosny Ali Elewa. Oral supplementation of policosanol alleviates carbon tetrachloride-induced liver fibrosis in rats. Biomedicine & Pharmacotherapy 2022; 150: 113020 doi: 10.1016/j.biopha.2022.113020
|
| 26 |
Xin Li, Mengli Yu, Qingwei Zhao, Yang Yu. Prospective therapeutics for intestinal and hepatic fibrosis. Bioengineering & Translational Medicine 2023; 8(6) doi: 10.1002/btm2.10579
|
| 27 |
Qiaoting Hu, Mingyu Liu, Yundan You, Guo Zhou, Ye Chen, Hui Yuan, Lulu Xie, Shisong Han, Kangshun Zhu. Dual inhibition of reactive oxygen species and spleen tyrosine kinase as a therapeutic strategy in liver fibrosis. Free Radical Biology and Medicine 2021; 175: 193 doi: 10.1016/j.freeradbiomed.2021.08.241
|
| 28 |
Yanwei LI, Yunrui LU, Mozuo NIAN, Qiuju SHENG, Chong ZHANG, Chao HAN, Xiaoguang DOU, Yang DING. Therapeutic potential and mechanism of Chinese herbal medicines in treating fibrotic liver disease. Chinese Journal of Natural Medicines 2023; 21(9): 643 doi: 10.1016/S1875-5364(23)60443-1
|